Compass Therapeutics (CMPX) Non Operating Income (2019 - 2020)
Compass Therapeutics (CMPX) posted Non Operating Income of -$1.2 million for Q3 2020, down 18.42% sequentially from -$1.0 million in Q2 2020, and down 202.99% YoY from $1.2 million in Q4 2019.
Powered by 
Analysis
Compass Therapeutics (CMPX) Non Operating Income (2019 - 2020) Analysis & Trends
Compass Therapeutics has reported Non Operating Income for 2 years, with the latest figure at -$1.2 million in Q3 2020.
- Quarterly Non Operating Income fell 202.99% year-over-year to -$1.2 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was -$2.9 million (changed N/A YoY) and the FY2020 annual result came in at -$1.7 million, down 175.54% from the prior year.
- Non Operating Income fell to -$1.2 million in Q3 2020 per CMPX's latest filing, from -$1.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at -$258000.0 in Q2 2019 and troughed at -$1.2 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Compass Therapeutics | 452.99 Mn | 452.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | -1.22 Mn |
| Jun 30, 2020 | -1.03 Mn |
| Sep 30, 2019 | -401,000.00 |
| Jun 30, 2019 | -258,000.00 |